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To the Editor: The alpha-2 adrenergic agonist
brimonidine (Mirvaso) 0.33% gel was approved by
the US Food and Drug Administration in 2013,
for the topical treatment of persistent facial
erythema of rosacea, in adults 18 years of age or
older. Reported adverse reactions include erythema,
flushing, skin-burning sensation, and contact derma-
titis. We report a case of facial erythema of rosacea
that responded well to this medication, however,
rebounded with significantly greater erythema than
baseline for the patient.
A 29-year-old white woman with erythematote-
langiectatic rosacea involving cheeks and chin
presented for a trial of brimonidine for persistent
facial erythema. The patient had skin phototype I
(Fitzpatrick), and in addition to persistent erythema
had occasional flushing. Flushing in this patient was
triggered typically by caffeine intake, spicy foods,
and temperature changes. The patient applied a thin
layer of brimonidine 0.33% gel to her entire face in
the morning, and within 1 to 2 hours had
complete blanching of treated facial skin (Fig 1).
This effective blanching lasted for approximately
10 to 12 hours after application. However, 12 hours
after application facial erythema recurred and was
significantly increased from baseline, involving the
cheeks, chin, nose, and forehead. This increased
rebound erythema lasted for an additional 12 to 14
hours before facial erythema regressed to baselineFig 1. Rosacea. Central facial erythema of rosa
application of brimonidine within 2 hours, howev
was significant rebound erythema of the cheeks,
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of brimonidine 2 additional times, and had similar
outcomes.
Rosacea is a common condition, and various
subtypes are recognized including erythematotelan-
giectatic, papulopustular, phymatous, and ocular
rosacea.1 Various treatments are available but must
be tailored to the individual patient, depending on
the subtype of rosacea. One of the more difficult
aspects to treat is the facial erythema of rosacea,
which is thought to have a complex pathogenesis
involving altered blood flow, vascular dilation and
proliferation, and permanent dilation of superficial
vessels.2 Brimonidine is a newly approved topical
medication for the treatment of facial erythema of
rosacea. It is an agonist of alpha-2 adrenergic
receptors, which are located in the smooth-muscle
sheath that encase vessel walls of superficial
cutaneous blood vessels.2 We report a patient who
had effective vascular constriction with topical
application of brimonidine, with decreased facial
erythema to all areas treated. However, the patient
developed a significant rebound facial erythema
greater than baseline erythema approximately 12
hours after application. This rebound erythema
lasted at least an additional 12 hours. Although
this significant rebound erythema appears to be
temporary, patients should be counseled on this
potential side effect.
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Fig 1. Trigeminal trophic syndrome. Left facial erosions,
scarring, and ulceration of the tragus.
Fig 2. Axial T1-weighted magnetic resonance imaging of
the brain. Left- and right-sided meningiomas (black
arrowheads) and trigeminal nerves (white arrowheads).
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Trigeminal trophic syndrome secondary to
recurrent meningioma
To the Editor: A 45-year-old man with a history of
childhood acute lymphocytic leukemia and
radiation-induced bilateral recurrent meningiomas
requiring resection in 2001 and resection and
Gamma-Knife in 2010 presented with a 4-week
history of unexplained facial ulcerations followed
by the development of headaches. He reported
waking with ‘‘bloody lesions’’ on his face, which
were preceded by facial pain he rated on a scale of 1
to 10 as an 8. He denied pruritus and picking his face.
His headaches were associatedwith left-sided photo-
phobia and facial numbness. Physical exam revealed
a red, ulcerated, indurated left tragus. Scattered 5- to
10-mm annular pink atrophic scars with peripheral
hyperpigmentation were seen on the left cheek,
forehead, and nose (Fig 1). A 2- x 1-cm superficial
ulceration within a well-healed surgical scar and a
1.2-cm x 6-mm crescentic superficial ulceration on
the left lateral nose were noted. Dried blood was
noted under his fingernails. Neurologic exam re-
vealed diminished sensation to touch, pinprick, and
temperature on the left side of the face.
Complete blood count with differential, complete
metabolic profile, and liver function tests were
normal. Skin biopsy of the left tragus showed normal
skin without evidence of malignancy or significant
inflammation. Brain magnetic resonance imaging
study showed a left middle cranial fossa meningioma
with interval enlargement compared with the
previous year with involvement of the ipsilateral
trigeminal nerve (Fig 2). A right posterior clinoid
meningioma, unchanged from the previous study,was also present. Trigeminal trophic syndrome (TTS)
involving all 3 branches of the trigeminal nerve was
diagnosed.
TTS, also called trigeminal neurotrophic
ulceration, is a rare condition occurring after damage
to the trigeminal nerve and presents with unilateral
anesthesia with crescentic ulceration classically
involving the ala nasi. Ulceration is self-induced
secondary to paresthesias and patients are often
unaware of self-mutilation. Causes of trigeminal
nerve damage leading to TTS include trigeminal
ablation, infarction, vertebrobasilar insufficiency,
acoustic neuroma, astrocytoma, meningioma, spinal
cord degeneration, Mycobacterium leprae neuritis,
herpes zoster, syringobulbia, postencephalitic
parkinsonism, and trauma.1
